Salute e Benessere

Precision Nutrition Market Expected to Reach USD 22.82 Billion by 2032 Amid…

Growth Drivers: Personalization Meets Clinical Outcomes Growth Drivers: Personalization Meets Clinical Outcomes As personalized health ecosystems expand, precision nutrition is becoming a central pillar in preventive healthcare, metabolic optimization, and long-term wellness management. Download PDF Brochure:https://www.datamintelligence.com/download-sample/precision-nutrition-market Browse in-depth TOC on "Precision Nutrition Market"70 – Tables 66 – Figures 195 – Pages...
PR Newswire
17/11/2025

AI in Personalized Nutrition Market to Reach USD 4.26 Billion by 2032, Driven by…

AI-driven nutrition systems-powered by deep learning, predictive analytics, and natural language processing are reshaping the global nutrition industry by offering 70–90% more precise recommendations than generalized diet frameworks. AI-driven nutrition systems-powered by deep learning, predictive analytics, and natural language processing are reshaping the global nutrition industry by offering70–90% more precise recommendationsthan generalized diet frameworks. Market Growth Drivers:...
PR Newswire
17/11/2025

Animal Wound Care Market worth US$1.79 billion by 2030 with 6.9% CAGR |…

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=253831778 Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=253831778 Browse in-depth TOC on "Animal Wound Care Market" 300 - Tables 60 - Figures 350 - Pages By product,the animal wound care market for foam dressings is experiencing significant growth due to several key factors that highlight the effectiveness and versatility of foam-based wound care solutions...
PR Newswire
17/11/2025

Canary Speech Receives Frost & Sullivan's 2025 North America Technology…

Frost & Sullivan evaluates companies through a rigorous benchmarking process across two core dimensions: strategy effectiveness and strategy execution. Canary Speech excelled in both, demonstrating its ability to align strategic initiatives with market demand while executing them with efficiency, consistency, and scale. "Canary Speech believes that NLP-based early disease detection through speech analytics will become obsolete due to inherent inaccuracies and reproducibility…
PR Newswire
17/11/2025

Cosmos Health Reports Record Q3 2025 Results with All-Time High Revenue, Gross…

Cosmos Health Inc.("Cosmos Health" or the “Company”)(NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today reported financial results for the third quarter and nine-month period ended September 30, 2025. Financial Highlights for the Three and Nine Months Ended September 30, 2025Income StatementCosmos Health delivered a record quarter,achieving the highest revenue, gross profit, and gross margin in its history, along with a significant...
Nasdaq GlobeNewswire
17/11/2025

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives…

Bagsværd, Denmark, 17 November 2025 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s board members, executives and their associated persons have reported the transactions to Novo Nordisk. 1 Details of the person discharging managerial responsibilities/person closely associated...
Nasdaq GlobeNewswire
17/11/2025

Philips brings AI into the procedure room to assist doctors during heart valve…

Innovation uses AI to track and visualize tiny repair devices* through the beating heart, helping clinicians navigate in 3D with enhanced clarity and confidence**Amsterdam, the Netherlands –Royal Philips(NYSE: PHG, AEX: PHIA), a global leader in health technology, today introduced DeviceGuide, an AI-powered device tracking* solution that assists physicians during one of interventional cardiology’s most technically demanding procedures: repairing leaking heart valves through a...
Nasdaq GlobeNewswire
17/11/2025

T-knife Therapeutics Files Clinical Trial Application for Phase 1 ATLAS Trial…

-- Preclinical data with TK-6302 has shown best-in-class anti-tumor efficacy, demonstrating its potential to elicit deep and durable responses in diverse solid tumor indications with high unmet need-- Following CTA approval, Phase 1 ATLAS trial planned to begin in 2026 SAN FRANCISCO and BERLIN, Nov.17, 2025(GLOBE NEWSWIRE) -- T-knife Therapeutics, Inc., a biopharmaceutical company developing next-generation T cell therapies to fight cancer, today announced the filing of a Clinical...
Nasdaq GlobeNewswire
17/11/2025

Curium Consolidates New Biopharma Business and Sets Up Global Headquarters in…

Curium Biopharma will continue to lead discovery and new product development Strategic move aims to accelerate biopharma innovation and revolutionize the diagnosis and treatment of cancerCurium International headquarters remain in Paris, France, while the United States headquarters are in St Louis, Missouri ST. LOUIS, Nov.17, 2025(GLOBE NEWSWIRE) -- Curium, a company dedicated to using cutting edge technology and innovative science in nuclear medicine to diagnose and treat...
Nasdaq GlobeNewswire
17/11/2025

Biogen and Stoke Therapeutics Announce Publication of Two-Year Natural History…

– Despite treatment with standard-of-care anti-seizure medicines, children with Dravet syndrome experienced high seizure burden and plateaued in neurodevelopment, resulting in a widening gap relative to children with typical development –– Findings underscore the urgent need for new medicines that target the underlying genetic cause of Dravet syndrome to improve long-term outcomes – CAMBRIDGE, Mass. and BEDFORD, Mass., Nov.17, 2025(GLOBE NEWSWIRE) --Biogen Inc. (Nasdaq: BIIB)...
Nasdaq GlobeNewswire
17/11/2025

Immatics Announces Third Quarter 2025 Financial Results and Business Update

Anzu-cel (anzutresgene autoleucel, IMA203) PRAME Cell Therapy: Global, randomized, controlled Phase 3 trial, SUPRAME, in previously treated advanced melanoma ongoing; interim and final analyses will occur in 2026 Anzu-cel (IMA203) PRAME Cell Therapy: One-time infusion continues to show strong clinical benefit and favorable tolerability in 16 patients with metastatic uveal melanoma in latest update on Phase 1b data presented at the ESMO 2025 Presidential Symposium: cORR of 67%, mDOR of 11...
Nasdaq GlobeNewswire
17/11/2025

Zymeworks Announces Positive HERIZON-GEA-01 Phase 3 Results Supporting Ziihera®…

Ziihera® plus chemotherapy showed a clinically meaningful and statistically significant improvement in PFS versus trastuzumab and chemotherapy, and a clinically meaningful effect with a strong trend toward statistical significance for OS at the first OS interim analysisZiihera plus Tevimbra® (tislelizumab)and chemotherapydemonstrated clinically meaningful and statistically significant improvements in OS and PFS versus trastuzumab and chemotherapyResults support Ziihera’s...
Nasdaq GlobeNewswire
17/11/2025

High Dose Regimen of Nusinersen Receives Positive CHMP Opinion for the Treatment…

Positive CHMP opinion is based on data from the DEVOTE study which evaluated the high dose regimen of nusinersen in treatment-naive participants and those transitioning from the currently approved 12mg dose regimen 1 Final European Commission decision expected in January 2026SMA is a rare, genetic, neuromuscular disease that affects individuals of all ages 2 CAMBRIDGE, Mass., Nov.17, 2025(GLOBE NEWSWIRE) --Biogen Inc.(Nasdaq: BIIB) today announced the Committee for Medicinal...
Nasdaq GlobeNewswire
17/11/2025

Krinwave Expands Boundaries of Medical Imaging Using NVIDIA Jetson Thor

The system also breaks the diffraction limit to achieve super-resolution imaging, enabling high-definition visualization of adult cranial structures and propelling ultrasound imaging into a new era of super-resolution, precision, and intelligent diagnostics This leap in performance is enabled by NVIDIA's full-stack edge computing platform, including Jetson Thor. Kirinwave developers leveraged NVIDIA acceleration tools such as Nsight Profiler, NVIDIA CUDA, NVIDIA TensorRT, and NVIDIA JetPack to…
PR Newswire
17/11/2025

Fapon at MEDICA 2025: AI-Driven Breakthroughs in Diagnostic Solutions, Featuring…

Fapon is also showcasing its one-stop IVD solutions that include IVD raw materials, reagent services, and open-system instruments. Among these, the chemiluminescence one-stop solution stands out, leveraging high-performance core raw materials, a panel of over 70 self-developed assays, and the flexible Shine i-Series CLIA analyzers covering low to ultra-high throughput to precisely meet testing needs across various scenarios. Notably, Fapon's Shine mT8000 Fully Automatic Clinical Chemistry and…
PR Newswire
17/11/2025

Ozelle Launches Next-Generation AI + Complete Blood Morphology Solution at…

Developed to meet the growing demand for rapid and standardized testing, the solution introduces three key breakthroughs: Developed to meet the growing demand for rapid and standardized testing, the solution introduces three key breakthroughs: Beyond product innovation, Ozelle continues to build an intelligent diagnostic ecosystem where hematology, biochemistry, and immunology data converge under a unified AI framework — transforming fragmented workflows into continuous, data-driven care...
PR Newswire
17/11/2025

Zelluna ASA: New share capital registered

Oslo, Norway, 17 November, 2025:Reference is made to the stock exchange announcement made by Zelluna ASA (the "Company") on 3 November 2025 regarding the successful private placement of 5,500,000 new shares (the "Private Placement"), divided on a first tranche of 3,729,774 new shares ("Tranche 1") and a second tranche of 1,770,226 new shares, and the allocation of 315,639 new shares in the retail offering carried out via the PrimaryBid platform (the "Retail…
Nasdaq GlobeNewswire
17/11/2025

Interlinked advances to next phase - CE-MDR approved dual-use solution for…

"This is a strategic step for Interlinked. The fact that ReLink® can deliver high safety and functionality in both civilian care and field hospital environments demonstrates the strength of our platform. Our ambition is to promote patient safety – whether care is delivered at a major university hospital or in an emergency preparedness situation. The need is clear, and interest is growing rapidly," says Katarina Hedbeck, CEO and co-founder of Interlinked AB. "This is a strategic…
PR Newswire
17/11/2025

Glow This Winter: COSRX Reveals Unmissable Deals for Amazon Black Friday & Cyber…

Exclusive Sets, Unbeatable DealsFor Amazon Black Friday and Cyber Monday 2025, COSRX introduces exclusive Peptide and Snail value sets — combining two bestsellers, The 6 Peptide Skin Booster Serum and The Advanced Snail 96 Mucin Power Essence, and innovations at their most irresistible prices. Exclusively on Amazon, these glow-restoring essentials bring professional-level care and visible radiance to your winter skincare routine. Exclusive Sets, Unbeatable DealsForAmazon Black Friday and...
PR Newswire
17/11/2025

Cardiovalve Submits CE File for Approval Following Successful TARGET Study…

The TARGET Study Interim Results: "Safety and Performance of the Cardiovalve Replacement System for Tricuspid Regurgitation" were presented yesterday by Prof. Georg Nickenig, on behalf of the TARGET study investigators, during the Top Late-Breaking Trials session at PCR London valves Main Arena. The TARGET Study Interim Results : "Safety and Performance of the Cardiovalve Replacement System for Tricuspid Regurgitation" were presented yesterday by Prof.Georg Nickenig, on…
PR Newswire
17/11/2025

Ramsay Sante : conditions of availability and consultation of the preparatory…

PRESS RELEASE Paris, 14 thNovember 2025COMBINED GENERAL MEETING OF DECEMBER 11, 2025 Conditions of availability and consultation of the preparatory documents for the Ramsay Générale de Santé General Meeting of December 11, 2025 The shareholders of Ramsay Générale de Santé are invited to participate in the Combined General Meeting on Thursday, December 11, 2025, which will take place at 10 a.m. at the Apostrophe 83 avenue Marceau 75116 Paris.The...
Nasdaq GlobeNewswire
17/11/2025

Clue Expands Wearable Integrations with Withings, Ultrahuman, WHOOP, Huawei…

Clue , the #1 women-led period and cycle tracker trusted by over 100 million worldwide, has today announced expanded integrations with leading wearable partners Withings , Ultrahuman , WHOOP,Huawei , Polar , Fitbit , Luna and Noise - giving women and people with cycles access to a richer picture of their health. These new partnerships follow Clue’s existing relationship with ŌURA , which has been in place in 2023, and are part of the brand’s continued mission...
Nasdaq GlobeNewswire
17/11/2025

Inventiva announces full exercise of Underwriters’ Option, bringing proceeds of…

Daix (France), New York City (New York, United States), November 17, 2025– Inventiva (Euronext Paris and Nasdaq: IVA) (" Inventiva " or the " Company "), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (" MASH "), today announced that the underwriters of the previously announced public offering in the United States (the " Offering ") of 38,961,038…
Nasdaq GlobeNewswire
17/11/2025

TME Pharma announces receipt of agreements in principle to extend certain bond…

TME Pharma announces receipt of agreements in principle to extend certain bond agreementsBerlin, Germany , November 17, 2025, 08.00am CET–TME Pharma N.V. (Euronext Growth Paris: ALTME),a clinical-stage biotechnology company specializing in the development of novel therapies for cancer and eye diseases, announced today that certain holders of the bonds issued in May and August, 2025 have agreed in principle to extend the maturity of the bonds for a one year period. These bond...
Nasdaq GlobeNewswire
17/11/2025
Altri  Comunicati